|
Sign In to gain access to subscriptions and/or personal tools.
|
Gamma hydroxy butyrate abuse and dependency
Alejandro Gonzalez
Edward Myers Unit, Harpland Hospital, Stoke-On-Trent, UK, alejandro.gonzalez8{at}btinternet.com
David J. Nutt
Psychopharmacology Unit, University of Bristol, Dorothy Hodgkin Building, Bristol, UK
The recreational use of gamma hydroxy butyrate (GHB) has gained popularity over the last decade. GHB was initially sold as a safe bodybuilding and fat burning compound. It is now also widely abused by bodybuilders and young ravers. GHB attracts young people due the euphoria that it initially produces, and the claimed increase in sociability and sexual function (it is also known as liquid Ecstasy). Over the last few years, there has been an increase in the number of cases of GHB intoxication, dependence and severe withdrawal, as reported in medical literature. The situation is complicated by the use of GHB analogues, other toxic chemicals that are easily converted into GHB. GHB has recently been classified as a class C drug in the UK, but no provisions were made in relation to GHB analogues. GHB has been increasingly used in rape cases due to its capacity to produce intoxication and amnesia. The management of patients dependent on GHB is rather complicated due to the high doses of medication that they require to control withdrawal symptoms.
Key Words: GHB GHB analogues physical dependence ravers
Journal of Psychopharmacology, Vol. 19, No. 2,
195-204 (2005)
DOI: 10.1177/0269881105049041

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
W. Koek, S. L. Mercer, A. Coop, and C. P. France
Behavioral Effects of {gamma}-Hydroxybutyrate, Its Precursor {gamma}-Butyrolactone, and GABAB Receptor Agonists: Time Course and Differential Antagonism by the GABAB Receptor Antagonist 3-Aminopropyl(diethoxymethyl)phosphinic Acid (CGP35348)
J. Pharmacol. Exp. Ther.,
September 1, 2009;
330(3):
876 - 883.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Liu, J. Wu, J. Zhu, C. Kuei, J. Yu, J. Shelton, S. W. Sutton, X. Li, S. J. Yun, T. Mirzadegan, et al.
Lactate Inhibits Lipolysis in Fat Cells through Activation of an Orphan G-protein-coupled Receptor, GPR81
J. Biol. Chem.,
January 30, 2009;
284(5):
2811 - 2822.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Sellman, G. Robinson, and R. Beasley
Review: Should ethanol be scheduled as a drug of high risk to public health?
J Psychopharmacol,
January 1, 2009;
23(1):
94 - 100.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D.M. Wood, C. Warren-Gash, T. Ashraf, S.L. Greene, Z. Shather, C. Trivedy, S. Clarke, J. Ramsey, D.W. Holt, and P.I. Dargan
Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD)
QJM,
January 1, 2008;
101(1):
23 - 29.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A J Razenberg, J W F Elte, A P Rietveld, H C T van Zaanen, and M C. Cabezas
A 'smart' type of Cushing's syndrome
Eur. J. Endocrinol.,
December 1, 2007;
157(6):
779 - 781.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Nutt
Alcohol alternatives - a goal for psychopharmacology?
J Psychopharmacol,
May 1, 2006;
20(3):
318 - 320.
[PDF]
|
 |
|
|
|